PT - JOURNAL ARTICLE AU - Tegally, Houriiyah AU - Dellicour, Simon AU - Poongavanan, Jenicca AU - Mavian, Carla AU - Dor, Graeme AU - Fonseca, Vagner AU - Tagliamonte, Massimiliano S. AU - Dunaiski, Marcel AU - Moir, Monika AU - Wilkinson, Eduan AU - de Albuquerque, Carlos Frederico Campelo AU - Frutuoso, Livia C. V. AU - CLIMADE Consortium AU - Holmes, Edward C. AU - Baxter, Cheryl AU - Lessells, Richard AU - Kraemer, Moritz U.G. AU - Lourenço, José AU - Alcantara, Luiz Carlos Junior AU - de Oliveira, Tulio AU - Giovanetti, Marta TI - Dynamics and ecology of a multi-stage expansion of Oropouche virus in Brazil AID - 10.1101/2024.10.29.24316328 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.29.24316328 4099 - http://medrxiv.org/content/early/2024/10/30/2024.10.29.24316328.short 4100 - http://medrxiv.org/content/early/2024/10/30/2024.10.29.24316328.full AB - In March 2024, the Pan American Health Organization (PAHO) issued an alert in response to a rapid increase in Oropouche fever cases across South America. Brazil has been particularly affected, reporting a novel reassortant lineage of the Oropouche virus (OROV) and expansion to previously non-endemic areas beyond the Amazon Basin. Utilising phylogeographic approaches, we reveal a multi-scale expansion process with both short and long-distance dispersal events, and diffusion velocities in line with human-mediated jumps. We identify forest cover, banana and cocoa cultivation, temperature, and human population density as key environmental factors associated with OROV range expansion. Using ecological niche modelling, we show that OROV circulated in areas of enhanced ecological suitability immediately preceding its explosive epidemic expansion in the Amazon. This likely resulted from the virus being introduced into simultaneously densely populated and environmentally favourable regions in the Amazon, such as Manaus, leading to an amplified epidemic and spread beyond the Amazon. Our study provides valuable insights into the dispersal and ecological dynamics of OROV, highlighting the role of human mobility in colonisation of new areas, and raising concern over high viral suitability along the Brazilian coast.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch at CERI was supported by the South African Medical Research Council (SAMRC) with funds received from the National Department of Health. Modelling activities at KRISP and CERI are supported in part by grants from the Rockefeller Foundation (HTH 017), the Abbott Pandemic Defense Coalition (APDC), the National Institute of Health USA (U01 AI151698) for the United World Antivirus Research Network (UWARN), the INFORM Africa project through IHVN (U54 TW012041) and the eLwazi Open Data Science Platform and Coordinating Center (U2CEB032224), the SAMRC South African mRNA Vaccine Consortium (SAMVAC), European Union supported by the Global Health EDCTP3 Joint Undertaking and its members as well as Bill & Melinda Gates Foundation (101103171), European Union Horizon Europe Research and Innovation Programme (101046041), the Health Emergency Preparedness and Response Umbrella Program (HEPR Program), managed by the World Bank Group (TF0B8412), the GIZ commissioned by the Government of the Federal Republic of Germany, the UK Medical Research Foundation (MRF RG ICCH 2022 100069, also M.U.G.K.), and the Wellcome Trust for the Global.health project (228186/Z/23/Z, also M.U.G.K.). This study was also supported by the National Institutes of Health USA grant U01 AI151698 for the United World Arbovirus Research Network (UWARN), the CRP ICGEB RESEARCH GRANT 2020 Project CRP/BRA20 03, Contract CRP/20/03, and the Rede Unificada de Analises Integradas de Arbovirus de Minas Gerais (REDE UAI ARBO MG), financed by Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), grant number RED 00234 23. S. Dellicour acknowledges support from the Fonds National de la Recherche Scientifique (F.R.S. FNRS, Belgium; grant F.4515.22), from the Research Foundation Flanders (Fonds voor Wetenschappelijk Onderzoek Vlaanderen, FWO, Belgium; grant G098321N), and from the European Union Horizon 2020 projects MOOD (grant agreement 874850) and LEAPS (grant agreement 101094685). M. Giovanetti funding is provided by PON "Ricerca e Innovazione 2014-2020. The content and findings reported herein are the sole deduction, view and responsibility of the researcher/s and do not reflect the official position and sentiments of the funding agencies. E.C.H. is supported by a National Health and Medical Research Council (NHMRC) Investigator award (GNT2017197) and by AIR@InnoHK administered by the Innovation and Technology Commission, Hong Kong Special Administrative Region, China. The authors gratefully acknowledge the Global Consortium to Identify and Control Epidemics CLIMADE (https://climade.health/). M.U.G.K. acknowledges funding from The Rockefeller Foundation (PC 2022 POP 005), Google.org, the Oxford Martin School Programmes in Pandemic Genomics & Digital Pandemic Preparedness, European Union's Horizon Europe programme projects MOOD (#874850) and E4Warning (#101086640), the John Fell Fund, a Branco Weiss Fellowship and Wellcome Trust grants 225288/Z/22/Z, 226052/Z/22/Z, United Kingdom Research and Innovation (#APP8583).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NCBI Genbank, https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/o/oropoucheI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll genomic and disease occurrence data used in this study were already openly available before this study, and analysis scripts will be made openly available via an indexed repository by the time of final publication. During the peer-review process, this is made available on a private repository.